Over 80% of human proteins lack well-defined catalytic or enzymatic binding pockets, rendering them historical "undruggable" targets for conventional small-molecule inhibitor pharmacology. Targeted Protein Degradation (TPD)—pioneered by Proteolysis Targeting Chimeras (**PROTACs**) and **Molecular Glues**—revolutionizes pharmacology by hijacking the cell's endogenous **Ubiquitin-Proteasome System (UPS)** to selectively eliminate disease-causing proteins rather than merely blocking their active sites.
1. Molecular Mechanism: The Ternary Complex & Catalytic Degradation
A heterobifunctional PROTAC molecule consists of three distinct chemical domains:
- Target-Binding Warhead: A small molecule that binds specifically to the Protein of Interest (POI), such as an oncogenic transcription factor or scaffolding kinase.
- E3 Ligase Recruiting Ligand: A ligand that binds tightly to an endogenous E3 ubiquitin ligase—predominantly **Cereblon (CRBN)** via thalidomide derivatives, or **von Hippel-Lindau (VHL)**.
- Chemical Linker: A flexible or rigid polyethylene glycol (PEG) or alkyl chain optimizing spatial orientation between the POI and the E3 ligase.
Upon formation of the POI–PROTAC–E3 ligase **ternary complex**, the E3 ligase transfers ubiquitin molecules from an E2 conjugating enzyme onto lysine residues on the POI. The polyubiquitinated target protein is then recognized and degraded by the 26S proteasome into small peptide fragments. Because the PROTAC is not consumed during degradation, it releases from the complex to catalytically destroy additional target proteins (the **sub-stoichiometric catalytic event**).
2. PROTACs vs. Molecular Glues Comparison
| Pharmacological Parameter | PROTACs | Molecular Glues |
|---|---|---|
| Molecular Architecture | Bifunctional (Ligand + Linker + Warhead), High MW (700–1200 Da) | Monovalent compact small molecule ($<500 ext{ Da}$) |
| Binding Mechanism | Independently binds POI and E3 ligase before complexation | Binds E3 ligase directly, altering its surface topology to create an artificial binding pocket for the target protein |
| Lipinski's Rule of 5 Compliance | Frequently violates Rule of 5 ("Beyond Rule of 5" space) | Strictly compliant (Superior oral bioavailability) |